Posted by Michael Wonder on 22 May 2025
FDA approves Genentech’s Susvimo for diabetic retinopathy
22 May 2025 - Genentech announced today that the US FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy, a potentially blinding condition that affects almost 10 million people in the US and more than 100 million people globally.
It is the first and only FDA approved continuous delivery treatment shown to maintain vision in people with diabetic retinopathy with just one refill every nine months.
